Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Average Price Target of $15.33 According to Brokerages

Key Points

• Coya Therapeutics has a “Moderate Buy” consensus from seven analysts, with six buy ratings and one sell rating. The average 12-month price target is $15.33.
• COYA shares opened at $4.95, compared with a 52-week range of $3.71 to $7.75, giving the company a market capitalization of approximately $116.1 million.
• The company exceeded quarterly expectations, reporting a loss of $0.28 per share versus the estimated $0.35 loss and revenue of $0.24 million. However, it remains unprofitable, with a negative net margin of 270.22%.

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.33.

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating on shares of Coya Therapeutics in a research report on Friday, September 25th. Chardan Capital reiterated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Roth Capital reissued a "buy" rating and set a $12.00 price target on shares of Coya Therapeutics in a research note on Monday, August 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a report on Friday, July 17th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $4.95 on Friday. Coya Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $7.75. The firm has a market capitalization of $116.12 million, a P/E ratio of -4.63 and a beta of 0.58. The company's 50 day moving average price is $4.78 and its two-hundred day moving average price is $4.69.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, analysts expect that Coya Therapeutics will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Allworth Financial LP increased its position in Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company's stock valued at $76,000 after acquiring an additional 12,000 shares during the period. AXQ Capital LP acquired a new position in shares of Coya Therapeutics during the second quarter worth $116,000. Cetera Investment Advisers lifted its holdings in shares of Coya Therapeutics by 36.4% during the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company's stock worth $118,000 after purchasing an additional 8,000 shares during the period. Long Corridor Asset Management Ltd bought a new stake in shares of Coya Therapeutics in the second quarter worth $227,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Coya Therapeutics in the first quarter worth $161,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company's research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression.

The company's lead programs include COYA 101, an autologous Treg cell therapy in which a patient's cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.